JPWO2020252240A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020252240A5 JPWO2020252240A5 JP2021573832A JP2021573832A JPWO2020252240A5 JP WO2020252240 A5 JPWO2020252240 A5 JP WO2020252240A5 JP 2021573832 A JP2021573832 A JP 2021573832A JP 2021573832 A JP2021573832 A JP 2021573832A JP WO2020252240 A5 JPWO2020252240 A5 JP WO2020252240A5
- Authority
- JP
- Japan
- Prior art keywords
- independently selected
- optionally substituted
- alkyl
- group
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 112
- 229910052757 nitrogen Inorganic materials 0.000 claims description 73
- 125000005842 heteroatom Chemical group 0.000 claims description 64
- 125000006413 ring segment Chemical group 0.000 claims description 64
- 150000001875 compounds Chemical class 0.000 claims description 51
- 125000003545 alkoxy group Chemical group 0.000 claims description 39
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 36
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 31
- 125000001072 heteroaryl group Chemical group 0.000 claims description 30
- 229910052760 oxygen Inorganic materials 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 125000005843 halogen group Chemical group 0.000 claims description 26
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 24
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 125000002947 alkylene group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000005549 heteroarylene group Chemical group 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- -1 1,1,3,3-tetramethylbutyl Chemical group 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 5
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 claims description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000012948 isocyanate Chemical group 0.000 claims description 2
- 150000002513 isocyanates Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024208554A JP2025037981A (ja) | 2019-06-14 | 2024-11-29 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861714P | 2019-06-14 | 2019-06-14 | |
| US62/861,714 | 2019-06-14 | ||
| US201962955924P | 2019-12-31 | 2019-12-31 | |
| US62/955,924 | 2019-12-31 | ||
| PCT/US2020/037403 WO2020252240A1 (en) | 2019-06-14 | 2020-06-12 | Compounds and compositions for treating conditions associated with sting activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024208554A Division JP2025037981A (ja) | 2019-06-14 | 2024-11-29 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022536755A JP2022536755A (ja) | 2022-08-18 |
| JPWO2020252240A5 true JPWO2020252240A5 (enExample) | 2023-06-19 |
Family
ID=71465411
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573832A Pending JP2022536755A (ja) | 2019-06-14 | 2020-06-12 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| JP2024208554A Pending JP2025037981A (ja) | 2019-06-14 | 2024-11-29 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024208554A Pending JP2025037981A (ja) | 2019-06-14 | 2024-11-29 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230092163A1 (enExample) |
| EP (1) | EP3983383A1 (enExample) |
| JP (2) | JP2022536755A (enExample) |
| MA (1) | MA56193A (enExample) |
| PY (1) | PY2026348A (enExample) |
| TW (1) | TWI873145B (enExample) |
| UY (1) | UY38751A (enExample) |
| WO (1) | WO2020252240A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3817820A1 (en) | 2018-07-03 | 2021-05-12 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2020150439A1 (en) * | 2019-01-17 | 2020-07-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | ONO Pharmaceutical Co., Ltd. | Method of cancer therapy |
| EP4263531A2 (en) * | 2020-12-16 | 2023-10-25 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2022133046A2 (en) * | 2020-12-16 | 2022-06-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| US20240041843A1 (en) | 2020-12-22 | 2024-02-08 | Ifm Due, Inc. | Methods of treating cancer |
| JP2024502755A (ja) | 2020-12-22 | 2024-01-23 | アイエフエム デュー インコーポレイテッド | がんを処置する方法 |
| WO2022140403A1 (en) | 2020-12-22 | 2022-06-30 | Ifm Due, Inc. | Methods of treating cancer |
| EP4267129A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| EP4274824A1 (en) | 2021-01-08 | 2023-11-15 | IFM Due, Inc. | Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity |
| CN112920170B (zh) * | 2021-01-29 | 2023-06-20 | 中国医科大学 | N-（吲哚-5-基）芳香杂环酰胺类化合物及其制备方法和用途 |
| WO2022213335A1 (en) * | 2021-04-09 | 2022-10-13 | Beigene (Beijing) Co., Ltd. | Method for preparing intermediate of bcl-2 inhibitor |
| TW202317087A (zh) | 2021-08-10 | 2023-05-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關病況之化合物及組合物 |
| CN115710255B (zh) * | 2021-08-23 | 2025-05-06 | 上海交通大学 | 一类含有苯并杂环取代的脲类衍生物及其制备和用途 |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2024096753A1 (en) | 2022-11-02 | 2024-05-10 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
| IT202200024963A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio Kv7.2/Kv7.3 |
| CN117756698A (zh) * | 2022-12-16 | 2024-03-26 | 中国药科大学 | 脲类化合物及其作为sting抑制剂的医药用途 |
| WO2024151919A1 (en) * | 2023-01-13 | 2024-07-18 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2024233603A1 (en) * | 2023-05-09 | 2024-11-14 | Icagen, Llc | Novel carboxamide derivatives |
| WO2024263860A1 (en) * | 2023-06-22 | 2024-12-26 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN121532389A (zh) * | 2023-08-30 | 2026-02-13 | 江苏正大丰海制药有限公司 | 用于调节微小rna-124活性的化合物 |
| WO2025079045A1 (en) * | 2023-10-12 | 2025-04-17 | Novartis Pharma Ag | Compounds and compositions for treating conditions associated with sting activity |
| WO2025153990A1 (en) * | 2024-01-19 | 2025-07-24 | Novartis Pharma Ag | Compounds and compositions for treating conditions associated with sting activity |
| WO2025188646A1 (en) * | 2024-03-04 | 2025-09-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for treating cancer |
| CN120794982A (zh) * | 2024-05-14 | 2025-10-17 | 中国药科大学 | 吡唑类sting抑制剂及其医药用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06500551A (ja) * | 1990-09-13 | 1994-01-20 | ビーチャム・グループ・パブリック・リミテッド・カンパニー | ５ｈｔ受容体アンタゴニストとしてのインドールウレア |
| US5439906A (en) * | 1993-11-22 | 1995-08-08 | Merck & Co., Inc. | Antiarrhythmic benzodiazepines |
| US6093742A (en) * | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
| GB9823873D0 (en) * | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| ES2226785T3 (es) * | 1999-02-12 | 2005-04-01 | Smithkline Beecham Plc | Derivados de fenilurea como antagonistas de los receptores de orexina. |
| US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| DE60208630T2 (de) * | 2001-05-11 | 2006-08-17 | Pfizer Products Inc., Groton | Thiazolderivate und ihre Verwendung als cdk-Inhibitoren |
| JP2003192587A (ja) * | 2001-12-26 | 2003-07-09 | Bayer Ag | 尿素誘導体 |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| UY28213A1 (es) * | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| US20060199846A1 (en) * | 2005-01-14 | 2006-09-07 | Mitchell Scott A | Certain substituted ureas as modulators of kinase activity |
| ATE517883T1 (de) * | 2005-08-25 | 2011-08-15 | Schering Corp | Imidazolderivate als funktionelle selektive agonisten des alpha2c-adrenorezeptors |
| CA2674865A1 (en) * | 2007-01-15 | 2008-07-24 | Santen Pharmaceutical Co., Ltd. | Indole derivative having i.kappa.b kinase .beta. inhibitory activity |
| EP2226315A4 (en) * | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | 2-aminoquinazoline DERIVATIVE |
| US9701631B2 (en) | 2010-12-03 | 2017-07-11 | The Trustees Of The University Of Pennsylvania | TIP60 inhibitors |
| KR20160065858A (ko) | 2013-10-21 | 2016-06-09 | 드렉셀유니버시티 | 만성 b형 간염 바이러스 감염을 치료하기 위한 스팅 효능제의 사용 |
| CA2993809C (en) * | 2015-07-30 | 2023-09-05 | Taipei Medical University | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system |
| US20170146519A1 (en) * | 2015-11-20 | 2017-05-25 | Oregon Health & Science University | Sting agonists and methods of selecting sting agonists |
| US20200172483A1 (en) * | 2017-06-22 | 2020-06-04 | Curadev Pharma Limited | Heterocyclic small molecule modulators of human sting |
| CN111132972B (zh) * | 2017-06-22 | 2024-07-12 | 克拉德夫制药有限公司 | 人sting的小分子调节剂 |
| CN111315723A (zh) * | 2017-08-31 | 2020-06-19 | 艾伯维公司 | 膜外核苷酸焦磷酸酶-磷酸二酯酶1(enpp-1)抑制剂及其用途 |
| EP3556362A1 (en) * | 2018-04-16 | 2019-10-23 | Ecole Polytechnique Federale De Lausanne (Epfl) | Sting inhibitors |
| EP3818044A1 (en) * | 2018-07-03 | 2021-05-12 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP3817820A1 (en) * | 2018-07-03 | 2021-05-12 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN109734677A (zh) * | 2019-03-07 | 2019-05-10 | 四川大学 | 抑制组蛋白赖氨酸甲基转移酶nsd2的小分子化合物及其应用 |
-
2020
- 2020-06-12 US US17/618,345 patent/US20230092163A1/en not_active Abandoned
- 2020-06-12 EP EP20736815.0A patent/EP3983383A1/en not_active Withdrawn
- 2020-06-12 JP JP2021573832A patent/JP2022536755A/ja active Pending
- 2020-06-12 WO PCT/US2020/037403 patent/WO2020252240A1/en not_active Ceased
- 2020-06-12 MA MA056193A patent/MA56193A/fr unknown
- 2020-06-15 UY UY0001038751A patent/UY38751A/es not_active Application Discontinuation
- 2020-06-15 TW TW109120089A patent/TWI873145B/zh active
- 2020-06-15 PY PY202002026348A patent/PY2026348A/es unknown
-
2024
- 2024-11-29 JP JP2024208554A patent/JP2025037981A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020252240A5 (enExample) | ||
| JP2026048714A (ja) | 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸 | |
| CA2889446C (en) | Combination therapies for the treatment of alzheimer's disease and related disorders | |
| JP6196986B2 (ja) | 麻酔化合物および関連する使用方法 | |
| US8168827B2 (en) | Amide derivative | |
| US12391664B2 (en) | GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor | |
| JP4399862B2 (ja) | 腸疾患および内臓痛の治療薬 | |
| US20050009812A1 (en) | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | |
| CN101842013A (zh) | 可用于治疗包括肥胖症和糖尿病的代谢疾患的大麻素受体拮抗剂/逆激动剂 | |
| PT2046740E (pt) | Compostos com atividade antagonista do crth2 | |
| JP2006517591A5 (enExample) | ||
| JP2008503585A5 (enExample) | ||
| JP2009543843A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| JP2008505107A5 (enExample) | ||
| CA2500977A1 (en) | 2-thiohydantoine derivative compounds and use thereof in therapeutics | |
| LU85847A1 (fr) | Amides et esters dihydropyridinyldicarboxyliques pharmaceutiquement utiles | |
| JP2007523909A5 (enExample) | ||
| JP2007537289A5 (enExample) | ||
| US11046657B2 (en) | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | |
| CN101384549B (zh) | 吡咯衍生物或其盐 | |
| US20210267993A1 (en) | Thiadiazine derivatives | |
| JPS61227567A (ja) | １，４−ジヒドロピリジン誘導体 | |
| IL279497B1 (en) | Treatment of protein in the urine | |
| WO2010098286A1 (ja) | ミネラルコルチコイド受容体拮抗薬を含有する医薬 |